Daurismo OverviewGlasdegib (PF-04449913) is an FDA approved cancer drug developed by Pfizer. It is a small molecule inhibitor of sonic hedgehog, which is a protein overexpressed in many types of cancer. It inhibits the sonic hedgehog receptor smoothened (SMO), as do most drugs in its class. Four phase II clinical trials are in progress. One is evaluating the efficacy of glasdegib in treating myelofibrosis in patients who were unable to control the disease with ruxolitinib....
Read more Daurismo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glasdegib
Recent Daurismo Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 100mg, 25mg
NDC Database Records for Daurismo: (2 results)Sorted by National Drug Code
- 0069-0298 Daurismo 25 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
- 0069-1531 Daurismo 100 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc